Literature DB >> 18061877

Pharmaceutical R&D in the spotlight: why is there still unmet medical need?

Esther F Schmid1, Dennis A Smith.   

Abstract

Huge amounts of money and knowledge have been poured into biomedical research for decades. Yet, in some disease areas next to no progress has been made in providing medical treatment. Importantly, it is not only neglected diseases where unmet medical need remains, but many diseases of 'rich' countries are also affected. Occasionally, new therapies exacerbate the medical need gap, such as in cancer. Our paper discusses some of the reasons why this might be and why all of society needs to find solutions to address unmet medical need.

Entities:  

Mesh:

Year:  2007        PMID: 18061877     DOI: 10.1016/j.drudis.2007.08.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  5 in total

Review 1.  APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use.

Authors:  David Cavalla
Journal:  Nat Rev Drug Discov       Date:  2009-08-28       Impact factor: 84.694

2.  Getting pharmaceutical R&D back on target.

Authors:  Mark E Bunnage
Journal:  Nat Chem Biol       Date:  2011-06       Impact factor: 15.040

Review 3.  Studying human disease using human neurons.

Authors:  Tim Ahfeldt; Nadia K Litterman; Lee L Rubin
Journal:  Brain Res       Date:  2016-04-06       Impact factor: 3.252

Review 4.  The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery.

Authors:  Anna Karawajczyk; Kristina M Orrling; Jon S B de Vlieger; Ton Rijnders; Dimitrios Tzalis
Journal:  Front Med (Lausanne)       Date:  2017-01-19

Review 5.  Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline.

Authors:  Carles Cornet; Vincenzo Di Donato; Javier Terriente
Journal:  Front Pharmacol       Date:  2018-07-03       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.